Chronická myeloidní leukemie - aktuální léčebné možnosti

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Chronic myeloid leukaemia - current treatment options
Authors

ČIČÁTKOVÁ Petra HORŇÁK Tomáš ŽÁČKOVÁ Daniela

Year of publication 2022
Type Article in Periodical
Magazine / Source Farmakoterapie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.farmakoterapie.cz/
Keywords chronic myeloid leukemia; tyrosine kinase inhibitors; treatment free remission
Description The chronic myeloid leukaemia (CML) treatment is based on tyrosine kinase inhibitors targeted to BCR::ABL1 tyrosine kinase. Their introduction has extended the life expectancy of patients with newly diagnosed disease to the level of healthy peers and nowadays, CML has an excellent prognosis. For the chronic phase CML therapy, imatinib and nilotinib are available in the first line in the Czech Republic. Nilotinib induces responses more rapidly, but its administration may be associated with serious side effects such as metabolic disorders or even life-threatening vascular events. Therefore, its administration should be considered individually and in routine practice it is used rather in younger and less comorbid patients. In case of intolerance or resistance, dasatinib, bosutinib and ponatinib are available and asciminib, the only allosteric inhibitor, has been gradually moving into the clinical practice. The therapy of blast crisis is still unsuccessful and the administration of intensive chemotherapy and often allogeneic transplantation of hematopoietic stem cells is usually necessary to cure the patient. Treatment-free remission has become a new goal of CML therapy, which is currently reserved for patients with a sustained deep molecular response and is maintained in about half of these patients. However, this represents only a small fraction of CML patients, 10–20%. We therefore hope that the factors predicting successful treatment-free remission will be identified soon, and availability of this procedure will increase significantly. This paper comprehensively summarizes current treatment options including new promising drugs in clinical trials.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info